HRP20110749T1 - Kombinacija agomelatina sa sredstvom za stabiliziranje raspoloženja i farmaceutski pripravci koji ga sadržavaju - Google Patents

Kombinacija agomelatina sa sredstvom za stabiliziranje raspoloženja i farmaceutski pripravci koji ga sadržavaju Download PDF

Info

Publication number
HRP20110749T1
HRP20110749T1 HR20110749T HRP20110749T HRP20110749T1 HR P20110749 T1 HRP20110749 T1 HR P20110749T1 HR 20110749 T HR20110749 T HR 20110749T HR P20110749 T HRP20110749 T HR P20110749T HR P20110749 T1 HRP20110749 T1 HR P20110749T1
Authority
HR
Croatia
Prior art keywords
agomelatine
association
pharmaceutical compositions
combination
disorder
Prior art date
Application number
HR20110749T
Other languages
English (en)
Inventor
De Bodinat Christian
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36190792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110749(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20110749T1 publication Critical patent/HRP20110749T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uporaba farmaceutskog pripravka koji sadržava agomelatin ili jedan od njegovih hidrata, kristalni oblik i adicijske soli farmaceutski prihvatljive kiseline ili baze u kombinaciji sa sredstvom za reguliranje rada timusa, naznačena time, da se ta uporaba odnosi na proizvodnju lijeka za liječenje teške depresije, ciklotimičnog poremećaja ili distimičnog poremećaja. Patent sadrži još jedan patentni zahtjev.

Claims (2)

1. Uporaba farmaceutskog pripravka koji sadržava agomelatin ili jedan od njegovih hidrata, kristalni oblik i adicijske soli farmaceutski prihvatljive kiseline ili baze u kombinaciji sa sredstvom za reguliranje rada timusa, naznačena time, da se ta uporaba odnosi na proizvodnju lijeka za liječenje teške depresije, ciklotimičnog poremećaja ili distimičnog poremećaja.
2. Uporaba kombinacije koja sadržava agomelatin ili jedan od njegovih hidrata, kristalni oblik i adicijske soli farmaceutski prihvatljive kiseline ili baze u kombinaciji sa sredstvom za reguliranje rada timusa, naznačena time, da se ta uporaba odnosi na dobivanje farmaceutskog pripravka za liječenje teške depresije, ciklotimičnog poremećaja ili distimičnog poremećaja.
HR20110749T 2005-09-09 2011-10-14 Kombinacija agomelatina sa sredstvom za stabiliziranje raspoloženja i farmaceutski pripravci koji ga sadržavaju HRP20110749T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509208A FR2890563B1 (fr) 2005-09-09 2005-09-09 Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
HRP20110749T1 true HRP20110749T1 (hr) 2011-11-30

Family

ID=36190792

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110749T HRP20110749T1 (hr) 2005-09-09 2011-10-14 Kombinacija agomelatina sa sredstvom za stabiliziranje raspoloženja i farmaceutski pripravci koji ga sadržavaju

Country Status (38)

Country Link
US (1) US7902180B2 (hr)
EP (2) EP1762238B1 (hr)
JP (1) JP2007077149A (hr)
KR (2) KR20070029607A (hr)
CN (1) CN1927194A (hr)
AP (1) AP3045A (hr)
AR (1) AR055418A1 (hr)
AT (1) ATE519482T1 (hr)
AU (1) AU2006209371B2 (hr)
BR (1) BRPI0603767A (hr)
CA (1) CA2558764C (hr)
CY (1) CY1112223T1 (hr)
DK (1) DK1762238T3 (hr)
EA (1) EA014381B1 (hr)
ES (1) ES2371482T3 (hr)
FR (1) FR2890563B1 (hr)
GE (1) GEP20094741B (hr)
GT (1) GT200600410A (hr)
HR (1) HRP20110749T1 (hr)
JO (1) JO2746B1 (hr)
MA (1) MA28504B1 (hr)
ME (1) ME01964B (hr)
MX (1) MXPA06010234A (hr)
MY (1) MY162318A (hr)
NO (1) NO338079B1 (hr)
NZ (1) NZ549727A (hr)
PE (1) PE20070613A1 (hr)
PL (1) PL1762238T3 (hr)
PT (1) PT1762238E (hr)
RS (1) RS52003B (hr)
SA (1) SA110320045B1 (hr)
SG (1) SG131029A1 (hr)
SI (1) SI1762238T1 (hr)
TW (1) TWI369980B (hr)
UA (1) UA83541C2 (hr)
UY (1) UY29776A1 (hr)
WO (1) WO2007028903A1 (hr)
ZA (1) ZA200607532B (hr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CZ20013786A3 (cs) * 1999-04-29 2002-02-13 Merck Patent Gmbh Inhibitory glycinového ątěpicího systému jako moľná antipsychotika
CN100525761C (zh) * 1999-12-01 2009-08-12 Ucb公司 用于治疗cns疾病的吡咯烷乙酰胺衍生物或者其组合物
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Also Published As

Publication number Publication date
US20070066689A1 (en) 2007-03-22
UY29776A1 (es) 2006-11-30
SG131029A1 (en) 2007-04-26
PL1762238T3 (pl) 2011-12-30
EP1762238A1 (fr) 2007-03-14
JP2007077149A (ja) 2007-03-29
PE20070613A1 (es) 2007-07-30
EA014381B1 (ru) 2010-10-29
AR055418A1 (es) 2007-08-22
MA28504B1 (fr) 2007-04-03
MXPA06010234A (es) 2007-03-08
AU2006209371A1 (en) 2007-03-29
SI1762238T1 (sl) 2011-10-28
FR2890563A1 (fr) 2007-03-16
UA83541C2 (uk) 2008-07-25
NO338079B1 (no) 2016-07-25
ATE519482T1 (de) 2011-08-15
NO20064049L (no) 2007-03-12
EP1762238B1 (fr) 2011-08-10
PT1762238E (pt) 2011-09-01
WO2007028903A1 (fr) 2007-03-15
AP3045A (en) 2014-11-30
CN1927194A (zh) 2007-03-14
GT200600410A (es) 2007-05-21
CY1112223T1 (el) 2015-12-09
AP2008004380A0 (en) 2008-04-30
ES2371482T3 (es) 2012-01-03
TW200800860A (en) 2008-01-01
RS52003B (en) 2012-04-30
JO2746B1 (en) 2014-03-15
SA110320045B1 (ar) 2014-01-29
CA2558764A1 (fr) 2007-03-09
KR20090056949A (ko) 2009-06-03
FR2890563B1 (fr) 2007-10-19
CA2558764C (fr) 2013-01-08
TWI369980B (en) 2012-08-11
AU2006209371B2 (en) 2012-02-02
ME01964B (me) 2012-04-30
BRPI0603767A (pt) 2007-08-14
DK1762238T3 (da) 2011-11-07
MY162318A (en) 2017-05-31
EP2301527A1 (fr) 2011-03-30
US7902180B2 (en) 2011-03-08
ZA200607532B (en) 2008-05-28
KR20070029607A (ko) 2007-03-14
EA200601450A1 (ru) 2007-04-27
NZ549727A (en) 2008-03-28
GEP20094741B (en) 2009-07-27

Similar Documents

Publication Publication Date Title
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
TNSN07360A1 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
TW200806300A (en) New therapeutic combinations for the treatment of depression
TW200738241A (en) Pyridazine derivatives
TW200716120A (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
TW200738280A (en) Novel pharmaceutical compositions comprising levetiracetam and process for their preparation
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
ECSP088405A (es) Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
TW200740764A (en) Pyrazolone derivatives
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
TN2010000038A1 (en) Organic compounds
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
SG179031A1 (en) Hsl inhibitors useful in the treatment of diabetes
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo